The FDA recently granted accelerated approval for the first-in-class KRAS (G12C) inhibitor sotorasib (Amgen Inc.)for patients with locally advanced or metastatic non-small cell lung cancer. This evidence concerns the gene KRAS and non-small cell lung carcinoma.